These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23034582)

  • 1. Clobazam : in patients with Lennox-Gastaut syndrome.
    Yang LP; Scott LJ
    CNS Drugs; 2012 Nov; 26(11):983-91. PubMed ID: 23034582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.
    Conry JA; Ng YT; Kernitsky L; Mitchell WG; Veidemanis R; Drummond R; Isojarvi J; Lee D; Paolicchi JM;
    Epilepsia; 2014 Apr; 55(4):558-67. PubMed ID: 24580023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome.
    Ng YT; Conry JA; Drummond R; Stolle J; Weinberg MA;
    Neurology; 2011 Oct; 77(15):1473-81. PubMed ID: 21956725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome.
    Owen RT
    Drugs Today (Barc); 2012 Nov; 48(11):697-703. PubMed ID: 23170305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience.
    Wheless JW; Isojarvi J; Lee D; Drummond R; Benbadis SR
    Epilepsy Behav; 2014 Dec; 41():47-52. PubMed ID: 25282105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study.
    Ng YT; Conry J; Paolicchi J; Kernitsky L; Mitchell W; Drummond R; Isojarvi J; Lee D; Owen R;
    Epilepsy Behav; 2012 Dec; 25(4):687-94. PubMed ID: 23141144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome.
    Tolbert D; Harris SI; Bekersky I; Lee D; Isojarvi J
    Epilepsy Behav; 2014 Aug; 37():11-5. PubMed ID: 24949576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clobazam and Aggression-Related Adverse Events in Pediatric Patients With Lennox-Gastaut Syndrome.
    Paolicchi JM; Ross G; Lee D; Drummond R; Isojarvi J
    Pediatr Neurol; 2015 Oct; 53(4):338-42. PubMed ID: 26245776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome.
    Cramer JA; Sapin C; François C
    Acta Neurol Scand; 2013 Aug; 128(2):91-9. PubMed ID: 23410109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clobazam approved for seizure disorder.
    Traynor K
    Am J Health Syst Pharm; 2011 Dec; 68(23):2204. PubMed ID: 22095800
    [No Abstract]   [Full Text] [Related]  

  • 11. Clobazam for patients with Lennox-Gastaut syndrome and epilepsy.
    Seif-Eddeine H; Ng YT
    Expert Rev Neurother; 2012 Apr; 12(4):385-93. PubMed ID: 22449211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
    McCormack PL
    Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clobazam (Onfi) for Lennox-Gastaut syndrome.
    Med Lett Drugs Ther; 2012 Mar; 54(1385):18-9. PubMed ID: 22382580
    [No Abstract]   [Full Text] [Related]  

  • 14. Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012.
    Isojarvi J; Lee D; Peng G; Sperling MR
    Epilepsia; 2016 Jun; 57(6):e113-6. PubMed ID: 27145465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome.
    Isojarvi J; Gidal BE; Chung S; Wechsler RT
    Epilepsy Behav; 2018 Jan; 78():149-154. PubMed ID: 29202277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study.
    Gidal BE; Wechsler RT; Sankar R; Montouris GD; White HS; Cloyd JC; Kane MC; Peng G; Tworek DM; Shen V; Isojarvi J
    Neurology; 2016 Oct; 87(17):1806-1812. PubMed ID: 27683846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome.
    Besag FMC; Vasey MJ
    Expert Opin Pharmacother; 2019 Sep; 20(13):1563-1574. PubMed ID: 31373526
    [No Abstract]   [Full Text] [Related]  

  • 19. Clobazam, ezogabine, and tafluprost.
    Hussar DA; Hallinan SE
    J Am Pharm Assoc (2003); 2012; 52(4):546-50. PubMed ID: 22825237
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term use of clobazam in Lennox-Gastaut syndrome: experience in a single tertiary epilepsy center.
    Lee EH; Yum MS; Choi HW; Ko TS
    Clin Neuropharmacol; 2013; 36(1):4-7. PubMed ID: 23334068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.